Navigation Links
Inverness Medical Innovations Announces Third Quarter 2008 Results
Date:10/29/2008

ax effect on adjustments as discussed above in notes (b), ( c ),

(d), (e) and (f).

(h) For the three months ended September 30, 2008 and 2007, potential

dilutive shares were not used in the calculation of diluted net loss

per common share under GAAP because inclusion thereof would be

antidilutive.

(i) Included in the weighted average diluted common shares for the

calculation of net income per common share for the three months

ended September 30, 2008, on an adjusted cash basis, are dilutive

shares consisting of 1,763,000 common stock equivalent shares from

the potential exercise of stock options and warrants and potential

dilutive shares consisting of 3,411,000 common stock equivalent

shares from the potential conversion of convertible debt securities.

The net income per diluted share calculation for the three months

ended September 30, 2008, on an adjusted cash basis, includes the

add back of interest expense related to the convertible debt of $0.7

million resulting in net income available to common stockholders of

$38.4 million. Potential dilutive shares consisting of 10,316,000

common stock equivalent shares from the potential conversion of

Series B convertible preferred stock for the three months ended

September 30, 2008 were not used in the calculation of diluted net

income per common share, on an adjusted cash basis, because

inclusion thereof would be antidilutive.

(j) Included in the weighted average dilutive common shares for the

calculation of net income per common share for the three months

ended September 30, 2007, on an adjusted cash basis, are dilutive

shares consisting of 3,227,000 common stock equivalent shares from

the potential exercise of
'/>"/>

SOURCE Inverness Medical Innovations, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related biology technology :

1. Inverness Medical Innovations Schedules Conference Call for 10:00 a.m. ET October 29, 2008 to Discuss Third Quarter 2008 Results
2. Inverness Medical Innovations to Present at the UBS Global Life Sciences Conference on September 22, 2008
3. Inverness Medical Innovations to Attend the Goldman Sachs Diagnostics Conference on September 18, 2008
4. Inverness Medical Innovations Declares Dividend on its Series B Convertible Perpetual Preferred Stock
5. Inverness Medical Innovations to Present at the Morgan Stanley Global Healthcare Unplugged Conference on September 9, 2008
6. Inverness Medical Innovations Features Innovative TB Diagnostic - Clearview(R) TB ELISA at AIDS 2008
7. Inverness Medical Innovations to Present at Canaccord Adams 28th Annual Growth Conference on August 12, 2008
8. Inverness Medical Innovations Announces Second Quarter 2008 Results
9. Inverness Medical Innovations to Present at Jefferies 2nd Annual Healthcare Conference held on June 25, 2008
10. Inverness Medical Innovations to Present at 7th Annual Needham & Company, LLC Biotechnology & Medical Technology Conference on June 12, 2008
11. Inverness Medical Innovations to Present at FBR Capital Markets 12th Annual Spring Investor Conference on May 28, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... 23, 2014 Nashville Fertility Center announced ... treasurer for the American Society for Reproductive Medicine (ASRM), ... research in reproductive medicine. In his new role ... the executive board and will have a voice in ... has actively supported ASRM since 1984 when he joined ...
(Date:12/24/2014)... BEIJING , Dec. 23, 2014 ... or the "Company"), a leading fully integrated plasma-based ... today announced that its majority-owned subsidiary, Shandong Taibang ... Practices ("GMP") certification from the China Food and ... factor production facility. As previously disclosed in the ...
(Date:12/24/2014)... Dec. 23, 2014 Sigma-Aldrich Corporation (NASDAQ: ... waiting period under the Hart-Scott-Rodino Antitrust Improvements Act ... on December 22, 2014, thereby completing the U.S. ... the acquisition of the Company by Merck KGaA, ... satisfies another condition to closing the transaction, which ...
(Date:12/22/2014)... 2014 The Center for Professional ... technical training across the life sciences industry, has partnered ... (SCDM) to provide the organization's members with discounted classroom ... to the more than 350 sessions across 80 course ... off when registering for a public course ...
Breaking Biology Technology:Nashville Fertility Center Announces Dr. George A. Hill Selected to Serve as ASRM Treasurer for 2014-15 2Nashville Fertility Center Announces Dr. George A. Hill Selected to Serve as ASRM Treasurer for 2014-15 3China Biologic Receives GMP Certification for New Coagulation Factor Facility 2China Biologic Receives GMP Certification for New Coagulation Factor Facility 3Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 2Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 3CfPIE Announces Partnership with the Society for Clinical Data Management 2CfPIE Announces Partnership with the Society for Clinical Data Management 3
... Belgium and LUND, Sweden, February 23 , ... of Partial Factor VIII Inhibition in,Patients Undergoing Knee Replacement ... Brussels: THR) and co-development partner,BioInvent International (OMXS: BINV) announce ... Phase II trial with their long-acting anticoagulant,TB-402 for the ...
... Approval and CommercializationSEATTLE, Feb. 20 Cell Therapeutics, Inc. ... exercised its option to sell its 50% ownership interest ... (Spectrum) for $18 million. CTI and Spectrum established a ... Zevalin. At that time CTI contributed all of the ...
... Feb. 20 Bariatric surgeons at Central,Baptist Hospital made ... procedure to decrease the capacity of a patient,s,stomach without ... the first,incisionless procedure of its kind performed in the ... Peter M. Denk, M.D., performed the procedure, dubbed,POSE (Primary ...
Cached Biology Technology:ThromboGenics and BioInvent Start Phase II Trial of TB-402, a Novel, Long Acting Anticoagulant for Deep Vein Thrombosis (DVT) Prophylaxis 2ThromboGenics and BioInvent Start Phase II Trial of TB-402, a Novel, Long Acting Anticoagulant for Deep Vein Thrombosis (DVT) Prophylaxis 3ThromboGenics and BioInvent Start Phase II Trial of TB-402, a Novel, Long Acting Anticoagulant for Deep Vein Thrombosis (DVT) Prophylaxis 4ThromboGenics and BioInvent Start Phase II Trial of TB-402, a Novel, Long Acting Anticoagulant for Deep Vein Thrombosis (DVT) Prophylaxis 5Cell Therapeutics Exercises Its Option to Sell Interest in Zevalin Joint Venture to Spectrum Pharmaceuticals for $18 Million 2Cell Therapeutics Exercises Its Option to Sell Interest in Zevalin Joint Venture to Spectrum Pharmaceuticals for $18 Million 3Cell Therapeutics Exercises Its Option to Sell Interest in Zevalin Joint Venture to Spectrum Pharmaceuticals for $18 Million 4Surgeons Perform First Incisionless Bariatric Procedure in the United States 2
(Date:12/4/2014)... BEACH GARDENS, Fla. , Dec. 3, 2014 ... management solutions, today announced that its DigitalPersona ® ... 4500 fingerprint readers have been deployed throughout First ... , South Carolina ... headquartered in Southern Pines, North Carolina ...
(Date:12/3/2014)... -- As part of our commitment to offering the ... announce the release of a new reader that will ... data that they need. The Atlas 2000 ... readers. Many such devices have serious shortcomings when it ... models force users to navigate numerous complicated steps in ...
(Date:11/21/2014)... YORK , Nov. 19, 2014  Earlier this ... at New York College, and one of the most ... biosensor signals that are transmitted from Smartphones to third ... were Smartphones and has one of the earliest known ... discussing its usage in the military, child care, elder ...
Breaking Biology News(10 mins):First Bank Partners with Crossmatch to Increase Log In Security 2First Bank Partners with Crossmatch to Increase Log In Security 3Inception Technologies to Release New Biometric Reader 2Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 2Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 4
... Washington, DCOrganic compounds contain carbon and hydrogen and form ... analyzing organic material and minerals in the Martian meteorite ... Laboratory have shown for the first time that building ... history. Previously, scientists have thought that organic material in ...
... quick and cool way to help combat climate change ... videos and stunning images are featured in Conservation Internationals ... calculate how much they are adding to global greenhouse ... to offset those emissions by helping protect tropical forests ...
... U.S. Department of,Homeland Security (DHS) is now ... Washington Dulles International Airport,(Dulles). The change is ... to 10-,fingerprint collection to enhance security and ... news or seen crimes solved on television,shows ...
Cached Biology News:Building blocks of life formed on Mars 2New carbon calculator conserves forests 2DHS Begins Collecting 10 Fingerprints From International Visitors at Washington Dulles International Airport 2
carnitine deficiency-associated gene expressed in ventricle 1...
HSV 1 IgG...
... R&D Systems adds two new Stem Cell ... stem cell products. The Human Embryonic Stem ... contains the antibodies against: alkaline phosphatase, Nanog, ... Stem Cell Marker Antibody Panel Plus (Catalog ...
... Printing Kit contains choice of Printing Surface (3 glass ... Ti adhesion layer, 1 silicon wafer coated with 1000 ... plain glass slides), PDMS Stamps (3 PDMS micropatterned stamps ... 100 um x 10 mm or 200 um x ...
Biology Products: